Compare IVDA & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVDA | PMCB |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.0M |
| IPO Year | 2015 | 2001 |
| Metric | IVDA | PMCB |
|---|---|---|
| Price | $0.21 | $128.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 127.7K | ★ 167.6K |
| Earning Date | 11-24-2026 | 12-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,468,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.98 | N/A |
| 52 Week Low | $0.18 | $0.25 |
| 52 Week High | $1.52 | $1.51 |
| Indicator | IVDA | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 98.99 |
| Support Level | $0.18 | $0.60 |
| Resistance Level | $0.34 | N/A |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | 0.00 | 0.42 |
| Stochastic Oscillator | 47.46 | 82.66 |
Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.